UPMC Enterprises has contributed to a series B round for Sempre Health, which is building a platform to make drugs more affordable for patients.
Sempre Health, a US-based dynamic drug pricing platform, completed a $15m series B round yesterday backed by UPMC Enterprises, the commercialisation arm of University of Pittsburgh Medical Center, a health system closely aligned with the institution.
Blue Venture Fund, which invests on behalf of 35 members of health insurance group Blue Cross Blue Shield Association, led the round, which additionally attracted Rethink Impact, LifeForce Capital and Industry Ventures.
Founded in 2015, Sempre Health is building a platform that…
